(IN BRIEF) The European Commission has approved Sanofi’s Teizeild as the first disease-modifying therapy in the EU to delay the onset of stage 3 type 1 diabetes in adults and children with stage 2 T1D. Supported by TN-10 phase 2 … Read the full press release →
Posted in Business, European Union, Financial, France, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune disease, beta cell function, CHMP, clinical approval, disease modifying therapy, EMA, European Commission, Sanofi, Sanofi’s Teizeild Becomes First EU-Approved Therapy to Delay Type 1 Diabetes Progression, T1D, Teizeild, teplizumab, TN-10 study, type 1 diabetes
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
